BSTG - Biostage Stock Price, News & Analysis

$0.07 0.00 (0.00 %)
(As of 11/24/2017 06:28 AM ET)
Previous Close$0.07
Today's Range$0.07 - $0.07
52-Week Range$0.05 - $1.42
Volume79,996 shs
Average Volume247,454 shs
Market Capitalization$2.73 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.07

About Biostage (OTCMKTS:BSTG)

Biostage logoBiostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.


Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:BSTG
  • Previous Symbol: NASDAQ:BSTG
  • CUSIPN/A

    Debt

    Debt-to-Equity RatioN/A
    Current Ratio1.10%
    Quick Ratio1.09%

    Price-To-Earnings

    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual Sales$80,000.00
    Price / Sales34.15
    Cash FlowN/A
    Price / CashN/A
    Book Value$0.10 per share
    Price / Book0.70

    Dividend

    Annual DividendN/A
    Dividend YieldN/A

    Profitability

    Trailing EPS($0.62)
    Net Income$-11,570,000.00
    Net MarginsN/A
    Return on Equity-592.04%
    Return on Assets-227.43%

    Miscellaneous

    Employees28
    Outstanding Shares39,030,000

    Frequently Asked Questions for Biostage (OTCMKTS:BSTG)

    What is Biostage's stock symbol?

    Biostage trades on the OTCMKTS under the ticker symbol "BSTG."

    How were Biostage's earnings last quarter?

    Biostage, Inc. (OTCMKTS:BSTG) announced its quarterly earnings data on Thursday, May, 11th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.09. View Biostage's Earnings History.

    Who are some of Biostage's key competitors?

    Who are Biostage's key executives?

    Biostage's management team includes the folowing people:

    • John F. Kennedy, Chairman of the Board (Age 66)
    • James J. McGorry, Chief Executive Officer, Director (Age 59)
    • Thomas McNaughton Jr., Chief Financial Officer (Age 54)
    • Harout DerSimonian, Chief Scientific Officer
    • David M. Green, Director (Age 50)
    • Blaine H Mckee Ph.D., Director
    • John J. Canepa, Independent Director (Age 59)
    • Thomas H. Robinson, Independent Director (Age 58)

    How do I buy Biostage stock?

    Shares of Biostage can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

    What is Biostage's stock price today?

    One share of Biostage stock can currently be purchased for approximately $0.07.

    How big of a company is Biostage?

    Biostage has a market capitalization of $2.73 million and generates $80,000.00 in revenue each year. The biotechnology company earns $-11,570,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Biostage employs 28 workers across the globe.

    How can I contact Biostage?

    Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The biotechnology company can be reached via phone at 774-233-7300 or via email at [email protected]


    MarketBeat Community Rating for Biostage (BSTG)

    Community Ranking:  2.9 out of 5 (star star)
    Outperform Votes:  70 (Vote Outperform)
    Underperform Votes:  52 (Vote Underperform)
    Total Votes:  122
    MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Biostage (OTCMKTS:BSTG)

      (How are Consensus Ratings Calculated?)
    Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings
    Consensus Rating:Hold (Score: 2.00)
    Analysts' Consensus Price Target: N/A

    Consensus Price Target History for Biostage (OTCMKTS:BSTG)

    Price Target History for Biostage (OTCMKTS:BSTG)

    Analysts' Ratings History for Biostage (OTCMKTS:BSTG)

    Show:
    DateFirmActionRatingPrice TargetDetails
    8/14/2017Maxim GroupReiterated RatingHoldView Rating Details
    (Data available from 11/24/2015 forward)

    Earnings

    Earnings History and Estimates Chart for Biostage (OTCMKTS:BSTG)

    Earnings by Quarter for Biostage (OTCMKTS:BSTG)

    Earnings History by Quarter for Biostage (OTCMKTS BSTG)

    DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
    8/14/2017Q2 2017($0.07)($0.10)ViewN/AView Earnings Details
    5/11/2017Q1 2017($0.23)($0.14)ViewN/AView Earnings Details
    3/9/2017Q4 2016($0.21)($0.20)$0.03 millionViewListenView Earnings Details
    11/10/2016Q316($0.25)($0.18)$26.00 millionViewN/AView Earnings Details
    8/11/2016Q216($0.21)($0.17)$48.00 million$0.03 millionViewListenView Earnings Details
    5/12/2016Q1($0.23)($0.18)ViewListenView Earnings Details
    3/17/2016Q415($0.17)$1.60 million$0.01 millionViewListenView Earnings Details
    11/12/2015Q315($0.19)$37.00 millionViewN/AView Earnings Details
    8/13/2015Q215($0.44)$23.00 million$73.00 millionViewN/AView Earnings Details
    3/19/2015Q4 2014($0.27)($0.36)$0.05 millionViewN/AView Earnings Details
    11/6/2014Q3 2014($0.33)($0.34)ViewN/AView Earnings Details
    8/8/2014Q214($0.27)($0.32)$0.02 millionViewN/AView Earnings Details
    5/8/2014Q114($0.33)($0.39)$0.10 million$0.02 millionViewN/AView Earnings Details
    (Data available from 1/1/2011 forward)

    Estimates

    Earnings Estimates for Biostage (OTCMKTS:BSTG)

    No earnings estimates for this company have been tracked by MarketBeat.com

    Dividends

    Dividend History for Biostage (OTCMKTS:BSTG)
    No dividend announcements for this company have been tracked by MarketBeat.com

    Insider Trades

    Insider Trading and Institutional Ownership History for Biostage (OTCMKTS BSTG)

    Insider Ownership Percentage: 4.30%
    Institutional Ownership Percentage: 5.90%
    Insider Trades by Quarter for Biostage (OTCMKTS:BSTG)

    Insider Trades by Quarter for Biostage (OTCMKTS BSTG)

    Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
    8/24/2017Saverio LafrancescaInsiderBuy100,000$0.37$37,000.00View SEC Filing  
    8/23/2017Saverio LafrancescaInsiderBuy150,000$0.32$48,000.00View SEC Filing  
    10/12/2016Harout DersimonianInsiderBuy10,000$0.91$9,100.00View SEC Filing  
    8/26/2016John F KennedyDirectorBuy16,182$0.93$15,049.26View SEC Filing  
    8/25/2016James Joseph McgorryInsiderBuy25,000$0.96$24,000.00View SEC Filing  
    6/21/2016James Joseph McgorryCEOBuy20,000$1.07$21,400.00View SEC Filing  
    6/13/2016Thomas H RobinsonDirectorBuy32,000$1.17$37,440.00View SEC Filing  
    5/25/2016John J CanepaDirectorBuy17,241$1.46$25,171.86View SEC Filing  
    5/20/2016James Joseph McgorryCEOBuy10,000$1.56$15,600.00View SEC Filing  
    5/20/2016John F KennedyDirectorBuy6,500$1.56$10,140.00View SEC Filing  
    5/20/2016Thomas McnaughtonCFOBuy5,000$1.56$7,800.00View SEC Filing  
    5/19/2016Thomas H RobinsonDirectorBuy18,000$1.36$24,480.00View SEC Filing  
    12/17/2015Saverio LafrancescainsiderSell2,393$1.93$4,618.49View SEC Filing  
    12/1/2015John F KennedyDirectorBuy9,000$2.95$26,550.00View SEC Filing  
    12/1/2015Saverio LafrancescaInsiderBuy10,000$3.01$30,100.00View SEC Filing  
    11/19/2015James Joseph McgorryCEOBuy10,000$1.79$17,900.00View SEC Filing  
    11/18/2015Thomas McnaughtonCFOBuy10,000$1.56$15,600.00View SEC Filing  
    11/17/2015David GreenDirectorBuy25,000$1.34$33,500.00View SEC Filing  
    11/17/2015Thomas McnaughtonCFOBuy15,000$1.32$19,800.00View SEC Filing  
    9/18/2015Saverio LafrancescainsiderBuy9,500$1.29$12,255.00View SEC Filing  
    8/28/2015Saverio LafrancescaInsiderBuy2,500$0.96$2,400.00View SEC Filing  
    8/26/2015Thomas McnaughtonCFOBuy10,000$0.88$8,800.00View SEC Filing  
    8/24/2015John F KennedyDirectorBuy12,000$0.83$9,960.00View SEC Filing  
    8/21/2015James Joseph McgorryCEOBuy31,300$0.74$23,162.00View SEC Filing  
    8/21/2015Thomas McnaughtonCFOBuy100,000$0.66$66,000.00View SEC Filing  
    6/4/2015John F KennedyDirectorBuy1,000$2.13$2,130.00View SEC Filing  
    6/3/2015John F KennedyDirectorBuy1,000$1.95$1,950.00View SEC Filing  
    6/3/2015Thomas McnaughtonCEOBuy16,000$1.85$29,600.00View SEC Filing  
    6/2/2015David GreenDirectorBuy26,600$1.81$48,146.00View SEC Filing  
    6/2/2015Thomas McnaughtonCEOBuy8,000$1.80$14,400.00View SEC Filing  
    6/1/2015John F KennedyDirectorBuy10,000$1.67$16,700.00View SEC Filing  
    6/1/2015Thomas McnaughtonCEOBuy3,000$1.74$5,220.00View SEC Filing  
    5/29/2015Thomas McnaughtonCEOBuy5,000$1.91$9,550.00View SEC Filing  
    2/18/2015David GreenCEOBuy50,000$1.75$87,500.00View SEC Filing  
    2/13/2015Thomas McnaughtonCFOBuy14,000$2.67$37,380.00View SEC Filing  
    (Data available from 1/1/2013 forward)

    Headlines

    Latest Headlines for Biostage (OTCMKTS BSTG)

    Source:
    No headlines for this company have been tracked by MarketBeat.com

    Social Media

    Financials

    Chart

    Biostage (OTCMKTS BSTG) Chart for Friday, November, 24, 2017
    Loading chart…

    This page was last updated on 11/24/2017 by MarketBeat.com Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.